AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...
ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315orKatherine Clock, 503-459-4974 and (NASDAQ: ARIA) today announced that MolecularMD has voluntarily withdrawn its ...
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its ...
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for ...
Complete remission (CR) rates exceed 90% when imatinib is used as frontline therapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia ...
In CML it is thought that the transforming event takes place in a multipotent stem cell, inferred from the range of cell lineages that have been shown to be Ph or BCR–ABL positive. 18 In Ph-positive ...
Asuragen will develop international scale calibrators and software reporting tools. Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory ...
The oncology landscape is rapidly evolving with new biomarker discoveries and potential targeted treatment options. Consequently, the medical community must work together to develop timely and ...
Patrick J. Muraca is president and chief executive cfficer, co-founder and board member of Pittsfield-based Nuclea Biotechnologies. PITTSFIELD — As Nuclea closed out a year of rapid growth, it signed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results